Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®): Pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium

Journal of Computer Assisted Tomography

Volumn 23, Issue SUPPL., 1999, Pages

  De Haën, Christoph ^a   Cabrini, Maurizio ^a   Akhnana, Lida ^a   Ratti, Danilo ^a   Calabi, Luisella ^a   Gozzini, Luigia ^a  

^a Bracco SpA   (Italy)

Author keywords

Complex formation constants; Gadobenate dimeglumine; MultiHance ; Pharmaceutical formulation; Physicochemical properties; Relaxivity

Indexed keywords

BODY FLUIDS; CONTRAST MEDIA; MAGNETIC RESONANCE IMAGING; MAGNETISM; METAL COMPLEXES;

COMPLEX FORMATION CONSTANTS; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; IMAGING CONTRAST; METAL COMPLEXATION; MULTIHANCE®; PHARMACEUTICAL FORMULATION; PHYSICOCHEMICAL PROPERTY; RELAXATION PROPERTY; RELAXIVITY;

THERMODYNAMIC STABILITY;

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIC ACID; GADOTERIDOL; MANGAFODIPIR;

COMPLEX FORMATION; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DRUG FORMULATION; DRUG STABILITY; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE; POTENTIOMETRY; PRIORITY JOURNAL; PROTON TRANSPORT; THERMOSTABILITY;

EID: 0343986280     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-199911001-00021     Document Type: Conference Paper

References (31)

1. Cavagna FM, Marzola P, Daprà M, et al. Binding of gadobenate dimeglumine to proteins extravasated into interstitial space enhances conspicuity of reperfused infarcts. Invest Radiol 1994;29 (Suppl 2):S50-3.
2. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-96.
3. Vittadini G, Felder E, Musu C, Tirone P. Preclinical profile of Gd-BOPTA, a liver specific contrast agent. Invest Radiol 1990;25 (Suppl. 1):S59-60.
4. Cavagna F, Tirone P, Felder E, de Haën C. Hepatobiliary contrast agents for MRI. In: Ferrucci JT, Stark DD, eds. Liver Imaging: Current Trends. Boston: Andover Medical Publishers, Reading, 1990:384-93.
5. de Haën C, La Ferla R, Maggioni F. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®) as contrast agent for magnetic resonance imaging of the liver. Mechanistic studies in animals. J Comput Assist Tomogr 1999;23 (suppl 1):S169-79.
6. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999;6: 282-91.
7. Morisetti A, Bussi S, Tirone P, de Haën C. Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance®), a new MRI contrast medium. J Comput Assist Tomogr 1999;23 (suppl 1):S207-17.
8. Cavagna FM, Saeed M, Wendland MF, et al. Names for gadobenate dimeglumine. Radiology 1996;198:908.
9. Felder E, Uggeri F, Fumagalli L, Vittadini G (Bracco Industria Chimica SpA). Paramagnetic chelates useful for NMR Imaging. US 4916246, April 10, 1990. IT 19236A, Jan. 30, 1986.
10. Davies A, de Haën C. Gadobenic acid dimeglumine salt, contrast agent for magnetic resonance imaging. Drugs Fut 1991;16(11):1001-3.
11. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln = Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11-triazatridecan-13-oato(5-)] gadolinate(2-) in a mixture with its enantiomer. Inorg Chem 1995;34:633-42.
12. OECD Guidelines No. 107, May 12, 1981 and No. 117, March 30, 1989.
13. OECD Guidelines No. 107, May 12, 1981 and No. 117, March 30, 1989.
14. Arbughi T, Bertani F, Celeste R, Grotti A, Sillari S, Tirone P. High-performance liquid Chromatographic determination of the magnetic resonance imaging contrast agent gadobenate ion in plasma, urine, faeces, bile and tissues. J Chromatogr B 1998;713:415-26.
15. de Haën C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR Imaging. J Magnet Reson Imag 1993;3:179-86.
16. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and toxicity of gadolinium complexes. Magnetic Reson Imag 1990;8:467-81.
17. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 1987;87:901-27.
18. Martin ML, Delpeuch JJ, Martin GJ. Practical NMR Spectroscopy. Chichester, England: Heyden, 1980.
19. 1-NMRD profiles of gadolinium(III) complexes of monoamide derivatives of DOTA-like ligands. X-ray structure of the 10-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-1-[(phenylmethoxy)methyl]-2-oxo- ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid-gadolinium (III) complex, Inorg Chem 1992;31:2422-8.
20. Vittadini G, Felder E, Tirone P, Lorusso V. B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 1988;23 (Suppl. 1):S246-8.
21. Lorusso V, Arbughi T, Tirone P, de Haën C. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance®). J Comput Assist Tomogr 1999;23 (suppl 1):S181-94.
22. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992;27: S1-6.
23. Chang CA. Magnetic resonance imaging contrast agents. Design and physicochemical properties of gadodiamide. Invest Radiol 1993;28:S21-7.
24. Rocklage SM, Cacheris WP, Quay SC, Hahn FE, Raymond KN. Manganese(II) N,N'-dipyridoxylethylenediamine-N,N'diacetate-5,5'-bis(phosphonate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem 1989;28:477-85.
25. Baumann EW. Investigation of copper (II) chelates of EDTA and DTPA with cupric-selective electrodes. J Inorg Nucl Chem 1974;36: 1827-32.
26. Bond J, Jones TI. Iron chelates of polyaminocarboxylic acids. Trans Faraday Soc 1959;55:1310-8.
27. Clarke ET, Martell AE. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13-, and 14-membered tetraazamacrocycles. Inorg Chim Acta 1991;190:37-46.
28. Schering AG, Berlin. Magnevist®. Nierengängiges paramagnetisches Kontrastmittel für die magnetische Resonanztomographie (MRT). 1987.
29. Tirkkonen B, Aukrust A, Couture E, et al. Physicochemical characterization of mangafodipir trisodium. Acta Radiol 1997;38: 780-9.
30. Weinmann H-J, Bauer H, Gries H, Radüchel B, Platzek J, Press W-R. New contrast agents for MRI. In: Rinck PA, ed. Contrast and contrast agents in magnetic resonance imaging Mons, Belgium: European Workshop on Magnetic Resonance in Medicine, State University, 1989:135-48.
31. Elizondo G, Fretz CJ, Stark DD, et al. Preclinical evaluation of Mn-DPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991;178:73-78.